Tramadol hcl: adverse event reports filed with FDA

5,799

reports as suspect product

0% of all reports · about 258 a year

19

reports, 12 months to June 2026

45 in the 12 months before

88.4%

marked serious by the reporter

91.7% across the class

23.2%

record death among outcomes, as reported

1,344 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Tramadol hcl reports recording the termmedian drug in opioid agonist

1. Drug interactionan interaction between medicines9.4%546
2. Completed suicidedeath by suicide7.9%458
3. Nauseafeeling sick6.3%366
4. Convulsion6.2%358
5. Confusional stateconfusion5.8%336
6. Vomitingbeing sick5.3%309
7. Overdosea dose above the recommended amount4.8%279
8. Somnolencedrowsiness4.6%268
9. Drug ineffectivethe medicine did not work as expected4.5%259
10. Drug hypersensitivityan allergic-type reaction to a medicine4.4%258
11. Serotonin syndrometoo much serotonin activity, with agitation, fever and tremor4.4%253
12. Dizzinesslight-headedness or unsteadiness4.2%246
13. Toxicity to various agentspoisoning or toxic effect of one or more substances3.8%219
14. Headachehead pain3.7%217
15. Painpain, site not specified3.5%203
16. Cardio-respiratory arrestthe heart and breathing stopped3.5%202
17. Falla fall3.3%193
18. Cardiac arrestthe heart stopped3.3%192
19. Deaththe patient died; cause not stated by this term3%176
20. Tremorshaking2.9%171
21. Drug abusemisuse of a medicine2.9%170
22. Respiratory arrestbreathing stopped2.9%170
23. Drug toxicity2.9%168
24. Hyperhidrosisexcessive sweating2.9%167
25. Dyspnoeashortness of breath2.8%164
26. Insomniadifficulty sleeping2.6%153
27. Astheniaweakness or lack of energy2.6%152
28. Loss of consciousnesspassing out2.6%150
29. Drug dependencedependence on a medicine2.6%148
30. Suicide attempta suicide attempt2.4%142

Top 30 of 1,029 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 42 drugs in the opioid agonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 965,051 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 48.5% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 5,799 reports.

Drugs most often listed in the same reports

Other products listed in reports where Tramadol hcl is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the opioid agonist class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Tramadol hcl as a suspect or interacting product; reports listing it only as a concomitant medication (31,611) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.